The Doncaster programme has been operational since mid-March 2021 and in the first year 11,857 lung health check calls and more than 5,000 initial scans have taken place; 50 lung cancers have been found, 73% of which were early-stage lung cancers. Seven other cancers have also been confirmed and 41 patients (75%) have been given life-saving cancer treatment so far.
Read more about this pioneering lung screening trial that is saving lives in Doncaster here
DART partner Optellum has attained CE marking in Europe.
This latest certification will allow for use in the European Union (EU) and the United Kingdom (UK), and opens the door to a European expansion for the growing company. It is the latest milestone for Optellum, which received FDA 510(k) clearance in early 2021 as the first AI-assisted diagnosis application for lung cancer. You can read the full press release online here.
In addition, researchers from the University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) have published the results of an academic study in European Radiology which takes a closer look at the Optellum Lung Cancer Prediction (LCP) model. You can read the full story on Optellum’s website here.